{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:05:52Z","timestamp":1787162752684,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-009634"],"award-info":[{"award-number":["MJFF-009634"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-023299"],"award-info":[{"award-number":["MJFF-023299"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson\u2019s disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Subjects with PD aged 50\u201379\u00a0years with baseline estimated glomerular filtration rate (eGFR)\u2009&gt;\u200960\u00a0mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9\u00a0weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation. A Bayesian modeling approach was used to estimate posterior probabilities (PP) of treatment effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 45 randomized patients, 44 were analyzed; 43 completed infusions, and 40 completed the 88-week follow-up. The three-infusion group (N\u2009=\u200916) showed an average annual eGFR increase of 3.29\u00a0mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , versus declines of \u20131.46 and \u20132.92 in the two-infusion (N\u2009=\u200914) and placebo (N\u2009=\u200915) groups. SCr decreased by \u20130.12\u00a0mg\/dL at both weeks 40 (PP: 93.9%) and 88 (PP: 86.2%) in the three-infusion group versus placebo, with no significant SCr differences between the two-infusion and placebo groups. BUN levels did not differ significantly between treatment and placebo groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In older adults with PD and preserved kidney function, repeated allo-hMSC infusions were associated with improved kidney function measures. While promising, these findings are preliminary and may be specific to PD. Further studies are needed to assess potential benefits in the broader aging population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.Gov. NCT04506073. November 09, 2020.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04506073\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT04506073<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-025-04577-y","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:26:14Z","timestamp":1758738374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson\u2019s disease clinical trial"],"prefix":"10.1186","volume":"16","author":[{"given":"Juan D.","family":"Martinez-Lemus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Molony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessika","family":"Suescun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Tharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tia S.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiamaka","family":"Onuigbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Robert","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9348-2587","authenticated-orcid":false,"given":"Mya C.","family":"Schiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"issue":"1","key":"4577_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41514-024-00148-2","volume":"10","author":"CH Jones","year":"2024","unstructured":"Jones CH, Dolsten M. Healthcare on the brink: navigating the challenges of an aging society in the United States. NPJ Aging. 2024;10(1):1\u201310. https:\/\/doi.org\/10.1038\/s41514-024-00148-2.","journal-title":"NPJ Aging"},{"issue":"100","key":"4577_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.arr.2014.01.004","volume":"14","author":"A Reeve","year":"2014","unstructured":"Reeve A, Simcox E, Turnbull D. Ageing and Parkinson\u2019s disease: why is advancing age the biggest risk factor? Ageing Res Rev. 2014;14(100):19\u201330. https:\/\/doi.org\/10.1016\/j.arr.2014.01.004.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"4577_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","volume":"41","author":"J Coresh","year":"2003","unstructured":"Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am J Kidney Dis. 2003;41(1):1\u201312. https:\/\/doi.org\/10.1053\/ajkd.2003.50007.","journal-title":"Am J Kidney Dis"},{"issue":"14","key":"4577_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu15143205","volume":"15","author":"MJ Kwon","year":"2023","unstructured":"Kwon MJ, Kim JK, Kim JH, Kim JH, Kim MJ, Kim NY, Choi HG, Kim ES. Exploring the link between chronic kidney disease and Parkinson\u2019s disease: insights from a longitudinal study using a national health screening cohort. Nutrients. 2023;15(14):1\u201315. https:\/\/doi.org\/10.3390\/nu15143205.","journal-title":"Nutrients"},{"issue":"1","key":"4577_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11011-020-00623-1","volume":"36","author":"JD Melendez-Flores","year":"2021","unstructured":"Melendez-Flores JD, Estrada-Bellmann I. Linking chronic kidney disease and Parkinson\u2019s disease: a literature review. Metab Brain Dis. 2021;36(1):1\u201312. https:\/\/doi.org\/10.1007\/s11011-020-00623-1.","journal-title":"Metab Brain Dis"},{"key":"4577_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19709-x","author":"H Peng","year":"2024","unstructured":"Peng H, Wu L, Chen Q, Chen S, Wu S, Shi X, Ma J, Yang H, Li X. Association between kidney function and Parkinson\u2019s disease risk: a prospective study from the UK Biobank. BMC Public Health. 2024. https:\/\/doi.org\/10.1186\/s12889-024-19709-x.","journal-title":"BMC Public Health"},{"issue":"3","key":"4577_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41593-024-01866-2","volume":"28","author":"X Yuan","year":"2025","unstructured":"Yuan X, Nie S, Yang Y, Liu C, Xia D, Meng L, Xia Y, Su H, Zhang C, Bu L, Deng M, Ye K, Xiong J, Chen L, Zhang Z. Propagation of pathologic alpha-synuclein from kidney to brain may contribute to Parkinson\u2019s disease. Nat Neurosci. 2025;28(3):577\u201388. https:\/\/doi.org\/10.1038\/s41593-024-01866-2.","journal-title":"Nat Neurosci"},{"issue":"4","key":"4577_CR8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.110.164780","volume":"57","author":"G Grassi","year":"2011","unstructured":"Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell\u2019Oro R, Mancia G. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57(4):846\u201351. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.164780.","journal-title":"Hypertension"},{"issue":"5","key":"4577_CR9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1161\/HYPERTENSIONAHA.109.136853","volume":"54","author":"EM Garland","year":"2009","unstructured":"Garland EM, Gamboa A, Okamoto L, Raj SR, Black BK, Davis TL, Biaggioni I, Robertson D. Renal impairment of pure autonomic failure. Hypertension. 2009;54(5):1057\u201361. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.136853.","journal-title":"Hypertension"},{"issue":"2","key":"4577_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/10937404.2016.1243501","volume":"20","author":"CC Bridges","year":"2017","unstructured":"Bridges CC, Zalups RK. The aging kidney and the nephrotoxic effects of mercury. J Toxicol Environ Health B Crit Rev. 2017;20(2):55\u201380. https:\/\/doi.org\/10.1080\/10937404.2016.1243501.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"issue":"1","key":"4577_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.ackd.2015.08.004","volume":"23","author":"A Denic","year":"2016","unstructured":"Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23(1):19\u201328. https:\/\/doi.org\/10.1053\/j.ackd.2015.08.004.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"8","key":"4577_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2215\/CJN.16631221","volume":"17","author":"ES Schaeffner","year":"2022","unstructured":"Schaeffner ES, Ebert N, Kuhlmann MK, Martus P, Mielke N, Schneider A, van der Giet M, Huscher D. Age and the course of GFR in persons aged 70 and above. Clin J Am Soc Nephrol. 2022;17(8):1119\u201328. https:\/\/doi.org\/10.2215\/CJN.16631221.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4577_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/ki.2012.443","volume":"83","author":"TC Turin","year":"2013","unstructured":"Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, Matsushita K, Hemmelgarn BR. Change in the estimated glomerular filtration rate over time and risk of all-cause mortality. Kidney Int. 2013;83(4):684\u201391. https:\/\/doi.org\/10.1038\/ki.2012.443.","journal-title":"Kidney Int"},{"issue":"4S","key":"4577_CR14","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKDWG","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes CKDWG. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"9","key":"4577_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41581-024-00868-4","volume":"20","author":"T Yamamoto","year":"2024","unstructured":"Yamamoto T, Isaka Y. Pathological mechanisms of kidney disease in ageing. Nat Rev Nephrol. 2024;20(9):603\u201315. https:\/\/doi.org\/10.1038\/s41581-024-00868-4.","journal-title":"Nat Rev Nephrol"},{"key":"4577_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.arr.2014.02.003","volume":"14","author":"D Bolignano","year":"2014","unstructured":"Bolignano D, Mattace-Raso F, Sijbrands EJ, Zoccali C. The aging kidney revisited: a systematic review. Ageing Res Rev. 2014;14:65\u201380. https:\/\/doi.org\/10.1016\/j.arr.2014.02.003.","journal-title":"Ageing Res Rev"},{"issue":"6","key":"4577_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.isci.2024.110045","volume":"27","author":"B Han","year":"2024","unstructured":"Han B, Zhang Y, Liu C, Ji P, Xing Z, Geng X, Chi K, Gong M, Li Y, Zhang Y, Fu Z, Hong Q, Cai G, Chen X, Sun X. Renal inflammation combined with renal function reserve reduction accelerate kidney aging via pentose phosphate pathway. iScience. 2024;27(6):1\u201316. https:\/\/doi.org\/10.1016\/j.isci.2024.110045.","journal-title":"iScience"},{"issue":"4","key":"4577_CR18","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/jgs.15268","volume":"66","author":"S Salimi","year":"2018","unstructured":"Salimi S, Shardell MD, Seliger SL, Bandinelli S, Guralnik JM, Ferrucci L. Inflammation and trajectory of renal function in community-dwelling older adults. J Am Geriatr Soc. 2018;66(4):804\u201311. https:\/\/doi.org\/10.1111\/jgs.15268.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"4577_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2215\/CJN.09280916","volume":"12","author":"J Schei","year":"2017","unstructured":"Schei J, Stefansson VTN, Eriksen BO, Jenssen TG, Solbu MD, Wilsgaard T, Melsom T. Association of TNF receptor 2 and CRP with GFR decline in the general nondiabetic population. Clin J Am Soc Nephrol. 2017;12(4):624\u201334. https:\/\/doi.org\/10.2215\/CJN.09280916.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"4577_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0108427","volume":"9","author":"D Medenwald","year":"2014","unstructured":"Medenwald D, Girndt M, Loppnow H, Kluttig A, Nuding S, Tiller D, Thiery JJ, Greiser KH, Haerting J, Werdan K. Inflammation and renal function after a four-year follow-up in subjects with unimpaired glomerular filtration rate: results from the observational, population-based CARLA cohort. PLoS ONE. 2014;9(9):1\u201311. https:\/\/doi.org\/10.1371\/journal.pone.0108427.","journal-title":"PLoS ONE"},{"issue":"4","key":"4577_CR21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1159\/000435863","volume":"5","author":"AC Carlsson","year":"2015","unstructured":"Carlsson AC, Nordquist L, Larsson TE, Carrero JJ, Larsson A, Lind L, Arnlov J. Soluble tumor necrosis factor receptor 1 is associated with glomerular filtration rate progression and incidence of chronic kidney disease in two community-based cohorts of elderly individuals. Cardiorenal Med. 2015;5(4):278\u201388. https:\/\/doi.org\/10.1159\/000435863.","journal-title":"Cardiorenal Med"},{"issue":"11","key":"4577_CR22","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/ki.2011.283","volume":"80","author":"A Shankar","year":"2011","unstructured":"Shankar A, Sun L, Klein BE, Lee KE, Muntner P, Nieto FJ, Tsai MY, Cruickshanks KJ, Schubert CR, Brazy PC, Coresh J, Klein R. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int. 2011;80(11):1231\u20138. https:\/\/doi.org\/10.1038\/ki.2011.283.","journal-title":"Kidney Int"},{"issue":"3","key":"4577_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/sj.ki.5002042","volume":"71","author":"CR Keller","year":"2007","unstructured":"Keller CR, Odden MC, Fried LF, Newman AB, Angleman S, Green CA, Cummings SR, Harris TB, Shlipak MG. Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int. 2007;71(3):239\u201344. https:\/\/doi.org\/10.1038\/sj.ki.5002042.","journal-title":"Kidney Int"},{"key":"4577_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2023.1181308","volume":"14","author":"J Li","year":"2023","unstructured":"Li J, Huang Y, Sun H, Yang L. Mechanism of mesenchymal stem cells and exosomes in the treatment of age-related diseases. Front Immunol. 2023;14:1\u201314. https:\/\/doi.org\/10.3389\/fimmu.2023.1181308.","journal-title":"Front Immunol"},{"issue":"5","key":"4577_CR25","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1161\/HYPERTENSIONAHA.110.150722","volume":"55","author":"DC Crews","year":"2010","unstructured":"Crews DC, Plantinga LC, Miller ER 3rd, Saran R, Hedgeman E, Saydah SH, Williams DE, Powe NR. Centers for disease C, prevention chronic kidney disease surveillance T. Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States. Hypertension. 2010;55(5):1102\u20139. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.150722.","journal-title":"Hypertension"},{"issue":"1","key":"4577_CR26","first-page":"49","volume":"5","author":"O Gheith","year":"2016","unstructured":"Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5(1):49\u201356.","journal-title":"J Nephropharmacol."},{"key":"4577_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcvm.2022.1035313","volume":"9","author":"DA Jaques","year":"2022","unstructured":"Jaques DA, Vollenweider P, Bochud M, Ponte B. Aging and hypertension in kidney function decline: a 10 year population-based study. Front Cardiovasc Med. 2022;9:1\u201310. https:\/\/doi.org\/10.3389\/fcvm.2022.1035313.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"4577_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.semnephrol.2009.07.002","volume":"29","author":"C Mei","year":"2009","unstructured":"Mei C, Zheng F. Chronic inflammation potentiates kidney aging. Semin Nephrol. 2009;29(6):555\u201368. https:\/\/doi.org\/10.1016\/j.semnephrol.2009.07.002.","journal-title":"Semin Nephrol"},{"key":"4577_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2022.892356","volume":"10","author":"K Tsuji","year":"2022","unstructured":"Tsuji K, Kitamura S, Wada J. Potential strategies for kidney regeneration with stem cells: an overview. Front Cell Dev Biol. 2022;10:1\u20137. https:\/\/doi.org\/10.3389\/fcell.2022.892356.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"4577_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22073576","volume":"22","author":"S Fernandez-Francos","year":"2021","unstructured":"Fernandez-Francos S, Eiro N, Costa LA, Escudero-Cernuda S, Fernandez-Sanchez ML, Vizoso FJ. Mesenchymal stem cells as a cornerstone in a galaxy of intercellular signals: basis for a new era of medicine. Int J Mol Sci. 2021;22(7):1\u201334. https:\/\/doi.org\/10.3390\/ijms22073576.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4577_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-024-03782-5","volume":"15","author":"M Taherian","year":"2024","unstructured":"Taherian M, Bayati P, Mojtabavi N. Stem cell-based therapy for fibrotic diseases: mechanisms and pathways. Stem Cell Res Ther. 2024;15(1):1\u201340. https:\/\/doi.org\/10.1186\/s13287-024-03782-5.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"4577_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5493\/wjem.v14.i3.97233","volume":"14","author":"N El Assaad","year":"2024","unstructured":"El Assaad N, Chebly A, Salame R, Achkar R, Bou Atme N, Akouch K, Rafoul P, Hanna C, Abou Zeid S, Ghosn M, Khalil C. Anti-aging based on stem cell therapy: a scoping review. World J Exp Med. 2024;14(3):1\u20137. https:\/\/doi.org\/10.5493\/wjem.v14.i3.97233.","journal-title":"World J Exp Med"},{"issue":"4","key":"4577_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-024-06620-x","volume":"15","author":"Z Chen","year":"2024","unstructured":"Chen Z, Xia X, Yao M, Yang Y, Ao X, Zhang Z, Guo L, Xu X. The dual role of mesenchymal stem cells in apoptosis regulation. Cell Death Dis. 2024;15(4):1\u201313. https:\/\/doi.org\/10.1038\/s41419-024-06620-x.","journal-title":"Cell Death Dis"},{"issue":"6","key":"4577_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/sji.13267","volume":"97","author":"W Chen","year":"2023","unstructured":"Chen W, Lv L, Chen N, Cui E. Immunogenicity of mesenchymal stromal\/stem cells. Scand J Immunol. 2023;97(6):1\u201311. https:\/\/doi.org\/10.1111\/sji.13267.","journal-title":"Scand J Immunol"},{"issue":"10","key":"4577_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20102406","volume":"20","author":"S Neri","year":"2019","unstructured":"Neri S. Genetic stability of mesenchymal stromal cells for regenerative medicine applications: a fundamental biosafety aspect. Int J Mol Sci. 2019;20(10):1\u201326. https:\/\/doi.org\/10.3390\/ijms20102406.","journal-title":"Int J Mol Sci"},{"key":"4577_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.891065","volume":"9","author":"C Zhou","year":"2022","unstructured":"Zhou C, Bai XY. Strategies for the induction of anti-inflammatory mesenchymal stem cells and their application in the treatment of immune-related nephropathy. Front Med (Lausanne). 2022;9: 1\u201310. https:\/\/doi.org\/10.3389\/fmed.2022.891065.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"4577_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12015-021-10231-w","volume":"18","author":"U Galderisi","year":"2022","unstructured":"Galderisi U, Peluso G, Di Bernardo G. Clinical trials based on mesenchymal stromal cells are exponentially increasing: where are we in recent years? Stem Cell Rev Rep. 2022;18(1):23\u201336. https:\/\/doi.org\/10.1007\/s12015-021-10231-w.","journal-title":"Stem Cell Rev Rep"},{"key":"4577_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/09636897231164251","volume":"32","author":"F Chen","year":"2023","unstructured":"Chen F, Chen N, Xia C, Wang H, Shao L, Zhou C, Wang J. Mesenchymal stem cell therapy in kidney diseases: potential and challenges. Cell Transplant. 2023;32:1\u201323. https:\/\/doi.org\/10.1177\/09636897231164251.","journal-title":"Cell Transplant"},{"issue":"8","key":"4577_CR39","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1002\/mds.28582","volume":"36","author":"M Schiess","year":"2021","unstructured":"Schiess M, Suescun J, Doursout MF, Adams C, Green C, Saltarrelli JG, Savitz S, Ellmore TM. Allogeneic bone marrow-derived mesenchymal stem cell safety in idiopathic Parkinson\u2019s disease. Mov Disord. 2021;36(8):1825\u201334. https:\/\/doi.org\/10.1002\/mds.28582.","journal-title":"Mov Disord"},{"issue":"19","key":"4577_CR40","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutierrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS, Chronic Kidney Disease Epidemiology C. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737\u201349. https:\/\/doi.org\/10.1056\/NEJMoa2102953.","journal-title":"N Engl J Med"},{"issue":"3","key":"4577_CR41","first-page":"515","volume":"1","author":"A Gelman","year":"2006","unstructured":"Gelman A. Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper). Bayes Anal. 2006;1(3):515\u201334.","journal-title":"Bayes Anal"},{"key":"4577_CR42","doi-asserted-by":"publisher","DOI":"10.1201\/9781482293456","volume-title":"Generalized linear models: a Bayesian perspective","author":"DK Dey","year":"2000","unstructured":"Dey DK, Ghosh SK, Mallick BK. Generalized linear models: a Bayesian perspective. Boca Raton, FL: CRC Press; 2000."},{"key":"4577_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.prdoa.2024.100274","volume":"11","author":"E Tharp","year":"2024","unstructured":"Tharp E, Martinez-Lemus JD, Schiess MC, Ellmore TM, Suescun J, Shahnawaz M. Role of alpha-synuclein seed amplification assay in Parkinson\u2019s disease clinical trials: a case of misdiagnosis. Clin Park Relat Disord. 2024;11:1\u20133. https:\/\/doi.org\/10.1016\/j.prdoa.2024.100274.","journal-title":"Clin Park Relat Disord"},{"issue":"12","key":"4577_CR44","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1212\/wnl.45.12.2143","volume":"45","author":"MC de Rijk","year":"1995","unstructured":"de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG, Hofman A. Prevalence of Parkinson\u2019s disease in the elderly: the Rotterdam study. Neurology. 1995;45(12):2143\u20136. https:\/\/doi.org\/10.1212\/wnl.45.12.2143.","journal-title":"Neurology"},{"issue":"4","key":"4577_CR45","doi-asserted-by":"publisher","first-page":"988","DOI":"10.2174\/1570159X20666220327212414","volume":"21","author":"A Unnisa","year":"2023","unstructured":"Unnisa A, Dua K, Kamal MA. Mechanism of mesenchymal stem cells as a multitarget disease-modifying therapy for Parkinson\u2019s disease. Curr Neuropharmacol. 2023;21(4):988\u20131000. https:\/\/doi.org\/10.2174\/1570159X20666220327212414.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"4577_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS, Investigators C-E. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1114248.","journal-title":"N Engl J Med"},{"key":"4577_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2023.1186224","volume":"14","author":"C Capelli","year":"2023","unstructured":"Capelli C, Cuofano C, Pavoni C, Frigerio S, Lisini D, Nava S, Quaroni M, Colombo V, Galli F, Bezukladova S, Panina-Bordignon P, Gaipa G, Comoli P, Cossu G, Martino G, Biondi A, Introna M, Golay J. Potency assays and biomarkers for cell-based advanced therapy medicinal products. Front Immunol. 2023;14:1\u201318. https:\/\/doi.org\/10.3389\/fimmu.2023.1186224.","journal-title":"Front Immunol"},{"key":"4577_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.918565","volume":"13","author":"ME Fernandez-Santos","year":"2022","unstructured":"Fernandez-Santos ME, Garcia-Arranz M, Andreu EJ, Garcia-Hernandez AM, Lopez-Parra M, Villaron E, Sepulveda P, Fernandez-Aviles F, Garcia-Olmo D, Prosper F, Sanchez-Guijo F, Moraleda JM, Zapata AG. Optimization of mesenchymal stromal cell (MSC) manufacturing processes for a better therapeutic outcome. Front Immunol. 2022;13:1\u201319. https:\/\/doi.org\/10.3389\/fimmu.2022.918565.","journal-title":"Front Immunol"},{"key":"4577_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01952","volume":"10","author":"RS Khan","year":"2019","unstructured":"Khan RS, Newsome PN. A comparison of phenotypic and functional properties of mesenchymal stromal cells and multipotent adult progenitor cells. Front Immunol. 2019;10:1\u201316. https:\/\/doi.org\/10.3389\/fimmu.2019.01952.","journal-title":"Front Immunol"},{"key":"4577_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2024.1330386","volume":"15","author":"A Tylutka","year":"2024","unstructured":"Tylutka A, Walas L, Zembron-Lacny A. Level of IL-6, TNF, and IL-1beta and age-related diseases: a systematic review and meta-analysis. Front Immunol. 2024;15:1\u201312. https:\/\/doi.org\/10.3389\/fimmu.2024.1330386.","journal-title":"Front Immunol"},{"key":"4577_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arr.2020.101151","volume":"63","author":"Y Fang","year":"2020","unstructured":"Fang Y, Gong AY, Haller ST, Dworkin LD, Liu Z, Gong R. The ageing kidney: molecular mechanisms and clinical implications. Ageing Res Rev. 2020;63:1\u201327. https:\/\/doi.org\/10.1016\/j.arr.2020.101151.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"4577_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-021-01432-5","volume":"21","author":"A Sondhi","year":"2021","unstructured":"Sondhi A, Segal B, Snider J, Humblet O, McCusker M. Bayesian additional evidence for decision making under small sample uncertainty. BMC Med Res Methodol. 2021;21(1):1\u20138. https:\/\/doi.org\/10.1186\/s12874-021-01432-5.","journal-title":"BMC Med Res Methodol"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04577-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04577-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04577-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:26:15Z","timestamp":1758738375000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-025-04577-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4577"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04577-y","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mya C. Schiess received financial support from the 2019 Clinical Therapeutic Pipeline Program Award by the Michael J. Fox Foundation for Parkinson\u2019s Research (Grant ID: MJFF-009634 and MJFF-023299). All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The study titled \u201cA Randomized, Double-Blind, Placebo-Controlled Trial of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells as a Disease-Modifying Therapy for Idiopathic Parkinson\u2019s Disease\u201d was approved by the Institutional Review Board (IRB) of the UTHealth Houston Committee for the Protection of Human Subjects (CPHS) under protocol number HSC-MS-20\u20130150, on April 8th, 2020. The protocol titled \u201cPilot Early \u2013 Phase I Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells Therapy for Idiopathic Parkinson\u2019s Disease\u201d for donor screening, bone marrow collection, and stem cell expansion was approved under protocol number HSC-MS-16\u20130026 on February 26th, 2016. Written informed consent was obtained from all participants for both study participation and the use of biological samples.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"493"}}